8-K: SurgePays Secures $2.5M in Public Stock Offering

SurgePays, Inc. announced an underwritten public offering of 2 million common shares at $1.25 each, raising approximately $2.5 million in gross proceeds.

Summary

• SurgePays, Inc. entered into an Underwriting Agreement on January 20, 2026, for an underwritten public offering of common stock.
• The offering consists of 2,000,000 shares of common stock at a public offering price of $1.25 per share.
• The aggregate gross proceeds from the offering are approximately $2.5 million, before deducting underwriting discounts, commissions, and other estimated offering expenses.
• The Company granted the underwriter a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price, less underwriting discounts, to cover over-allotments.
• Warrants (Representatives' Warrants) will be issued to the underwriter, allowing them to purchase a number of common stock shares equal to 3.0% of the total shares sold in this offering.
• The Representatives' Warrants will have an exercise price of $1.375 per share (110% of the public offering price).
• The Representatives' Warrants will be exercisable commencing six months after the closing date and will terminate five years after the commencement of sales in this offering.
• The net proceeds from the offering are intended for the expansion of the Company's Lifeline business, working capital, and general corporate purposes.
• The offering is expected to close on January 22, 2026.
• The Company also amended its At The Market Offering Agreement to allow for the sale of up to $1 in additional common stock through Titan Partners Group LLC, following previous sales of $1,775,390.79 through January 20, 2026.

Sentiment

Score: 7

Explanation: The filing describes a successful capital raise that provides the company with funds for business expansion and general corporate purposes. While there is dilution, securing financing is generally positive for growth-oriented companies.

Positives

• The Company successfully secured capital through an underwritten public offering, providing funds for business expansion and general corporate purposes.
• The proceeds are earmarked for growth initiatives, specifically the expansion of the Lifeline business, which could enhance future revenue streams.
• Maintaining an effective registration statement on Form S-3 facilitates future capital-raising activities.

Negatives

• The issuance of 2,000,000 new shares and the potential exercise of additional shares from the over-allotment option and Representatives' Warrants will result in dilution for existing shareholders.
• Underwriting discounts and commissions (7.0% of gross proceeds) and other offering expenses reduce the net proceeds available to the Company.
• The grant of a right of first refusal to the underwriter for future equity or debt offerings for three months may limit the Company's flexibility in choosing financing partners during that period.

Risks

• Forward-looking statements contained in the report involve substantial risks and uncertainties, and actual results may differ materially from those described.
• Risks and factors that could affect actual results are more fully described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and the final prospectus supplement.
• The issuance of new common stock and warrants will dilute the ownership percentage of current shareholders.
• The Company is subject to various laws and regulations, including federal and state securities laws, Exchange Act rules, and FINRA regulations, with potential for non-compliance.

Future Outlook

The Company intends to use the net proceeds from the offering for expansion of its Lifeline business, working capital, and general corporate purposes, indicating a focus on growth and operational funding.

Management Comments

• Management believes that the expectations reflected in their forward-looking statements are reasonable, acknowledging that these statements relate to future events or operational/financial performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially.

Industry Context

This capital raise provides SurgePays with additional funding to expand its Lifeline business, a segment focused on providing subsidized telecommunication services. This aligns with broader industry trends where companies in the telecom and fintech sectors seek capital for growth, particularly in underserved markets or specialized government programs.

Corporate Governance

Stakeholder Impact

• Shareholders will experience dilution from the issuance of 2,000,000 new shares and potential future dilution from the exercise of the 3.0% Representatives' Warrants and the over-allotment option. Existing shareholders are also subject to lock-up agreements.
• Executive officers and directors are subject to 180-day lock-up agreements on their securities.
• Company operations are expected to benefit from the capital raised, which is intended to fund the expansion of the Lifeline business, working capital, and general corporate purposes, potentially leading to increased operational capacity and growth.
• The underwriter (R.F. Lafferty & Co., Inc.) receives underwriting discounts and commissions (7.0% of gross proceeds) and Representatives' Warrants, along with a right of first refusal for future offerings.

Next Steps

• Closing of the underwritten public offering on January 22, 2026.
• Delivery of shares and Representatives' Warrants to the underwriter.
• Use of net proceeds for Lifeline business expansion, working capital, and general corporate purposes.
• Potential exercise of the over-allotment option by the underwriter within 45 days.
• Representatives' Warrants becoming exercisable six months after the closing date.
• Continued sales of common stock under the amended At The Market Offering Agreement.

Key Dates

Keywords

SurgePays, SURG, stock offering, public offering, common stock, warrants, capital raise, underwriting agreement, R.F. Lafferty & Co., Inc., Lifeline business, SEC filing, Form 8-K, equity financing, Nasdaq